ArticleThe international journal of cardiovascular imaging2026
In vivo cardiac diffusion tensor imaging quantifies microstructural disorganization to distinguish hypertrophic cardiomyopathy from hypertensive heart disease.
Article in The international journal of cardiovascular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate whether cardiac diffusion tensor imaging (cDTI) can discriminate hypertrophic cardiomyopathy (HCM) from hypertensive heart disease (HHD) based on microstructural alterations. MATERIALS AND
methodsThis prospective study enrolled 40 HCM patients and 14 HHD patients who underwent 3.0T cardiac magnetic resonance (CMR), including cDTI, T1 mapping and late gadolinium enhancement (LGE). Parameters of cDTI (mean diffusivity [MD], secondary eigenvector [E2A], helix angel [HA)] and fractional anisotropy [FA]) were compared across groups using analysis of covariance. Diagnostic performance was assessed using receiver operating characteristic analysis. A subgroup analysis was performed in HCM patients with mild hypertrophy (left ventricular wall thickness [LVWT] 13-19 mm).
resultsCompared to patients with HHD, those with HCM showed significantly greater LVWT, LGE extent, native T1 and extracellular volume fraction (ECV, all p < 0.05). cDTI revealed significant microstructural alterations in HCM, characterized by reduced FA (p = 0.001) and elevated E2A p < 0.001). Analysis of covariance confirmed these differences after adjusting for LVWT, native T1, and ECV. ROC analysis demonstrated that E2A (AUC = 0.88) and FA (AUC = 0.79) had superior diagnostic performance for distinguishing HCM from HHD, outperforming native T1 (AUC = 0.76), ECV (AUC = 0.75), and LGE extent (AUC = 0.67). In the HCM subgroup, E2A maintained the highest diagnostic performance (AUC = 0.86), followed by FA and ECV (both AUC = 0.73).
conclusionsE2A and FA derived from cDTI were robust biomarkers of microstructural alterations, enabling superior differentiation of HCM from HHD beyond conventional hypertrophy and fibrosis indices. These findings support the potential utility of cDTI in diagnosis of ambiguous hypertrophy.
Indexed as
Identifiers
41706393What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.